Status: Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Cinthya Yesenia Obando Perez
Phone: 346.238.6123
This study is for subjects that have high grade bladder cancer that has not entered the muscle. In the U.S., people who are not in a study are usually treated with BCG LIVE (TICE® BCG) (an abbreviation for Bacillus Calmette–Guérin), which is a b ... Read more >
Status: Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Pej Hemati
Phone: 713.441.3926
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spr ... Read more >
Status: Open Not Enrolling
Investigator: Brian Miles
Study Coordinator: Vivian MacDonnell
Phone: 714.441.8113
This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >
Status: Open Not Enrolling
Investigator: Richard Knight
Study Coordinator: Adam Daniels
Phone: 713.441.6232
The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also e ... Read more >
Status: Active
Investigator: Richard Knight
Study Coordinator: Alejandro De La Torre
Phone: 713.441.6396
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant. ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hyst ... Read more >
Status: Open Not Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants wi ... Read more >
Status: Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >
Status: Enrolling
Investigator: Kirk Heyne
Study Coordinator: Pej Hemati
Phone: 713.441.3926
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >
Status: Open Not Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have re ... Read more >
